clinical trial · NCT04167163
Abaloparatide Before Total Knee Arthroplasty
University of Wisconsin, Madison·phase4·completed·n = 58
OsteoporosisArthroplasties, Knee ReplacementAbaloparatide
brief summary
The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.
started
Jan 10, 2020
primary completion
Apr 3, 2025
completion
Apr 3, 2025
last updated
Apr 4, 2025
detailed description
In primary unilateral total knee arthroplasty patients, The investigator will examine the effect of daily abaloparatide therapy in clinical osteoporotic patients beginning 3 months pre-op and continued for a total of 15 months. This will be compared to osteopenic patients receiving no therapy as well as previously published values in untreated osteoporotic patients 12 months following Total Knee Arthroplasty (TKA).
official title
An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol